Assay Suitability for Natural Product Screening: Searching for Leads to Fight Alzheimerʼs Disease

Abstract

Phenotypic and target-based approaches represent two principal strategies for identifying new bioactive compounds. In this review, differences between these approaches, as well as strengths and limitations thereof, are described by examples from the therapeutic area of Alzheimerʼs disease. Some of the central mechanisms of the disease that today are targets of screening campaigns are described. These mechanisms include acetylcholinesterase inhibition, amyloid-based approaches, and oxidative stress. Examples of assays using natural products, either as isolated pure compounds, unpurified or partially purified extracts, are given for each mechanism. Further, the article presents and discusses the pros and cons of both target-based and phenotypic approaches for the chosen mechanisms. In most cases, a thoroughly biology-driven selection of the used assays can be recommended, especially when taking into account the complexity of the disease in question. However, target-based assays also have their justification as long as there is an awareness of what the assay read-out stands for. A clear recommendation is thus for every researcher to critically consider the aim of their bioactivity screening efforts and to adopt the screening strategies most appropriate for the goals set.

Key words

phenotypic assay - target-based assay - reductionistic - Alzheimerʼs disease - acetylcholinesterase - amyloid - oxidative stress

• References

• 1 Swinney DC, Anthony J. How were new medicines discovered?. Nat Rev Drug Discov 2011; 10: 507-519
• 2 Kell DB. Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it. FEBS J 2013; 280: 5957-5980
• 3 Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. Brit J Pharmacol 2011; 162: 1239-1249
• 4 Cragg GM, Newman DJ. Natural products: a continuing source of novel drug leads. Biochim Biophys Acta 2013; 1830: 3670-3695
• 5 Mishra BB, Tiwari VK. Natural products: An evolving role in future drug discovery. Eur J Med Chem 2011; 46: 4769-4807
• 6 Barker A, Kettle JG, Nowak T, Pease JE. Expanding medicinal chemistry space. Drug Discov Today 2013; 18: 298-304
• 7 López-Vallejo F, Giulianotti MA, Houghten RA, Medina-Franco JL. Expanding the medicinally relevant chemical space with compound libraries. Drug Discov Today 2012; 17: 718-726
• 8 Beutler JA. Natural products as a foundation for drug discovery. Curr Protoc Pharmacol 2009; 46: 1-9
• 9 Schmitt EK, Moore CM, Krastel P, Petersen F. Natural products as catalysts for innovation: a pharmaceutical industry perspective. Curr Opin Chem Biol 2011; 15: 497-504
• 10 Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112-2117
• 11 Bendlin BB, Carlsson CM, Gleason CE, Johnson SC, Sodhi A, Gallagher CL, Puglielli L, Engelman CD, Ries ML, Xu G, Wharton W, Asthana S. Midlife predictors of Alzheimerʼs disease. Maturitas 2010; 65: 131-137
• 12 Skape SD. Alzheimerʼs disease and amyloid: culprit or coincidence?. Int Rev Neurobiol 2012; 102: 277-316
• 13 Cummings JL, Banks SJ, Gary RK, Kinney JW, Lombardo JM, Ryan R, Walsh RR, Zhong K. Alzheimerʼs disease drug development: translational neuroscience strategies. CNS Spectr 2013; 18: 128-138
• 14 Misra S, Bikash B. Drug development status for Alzheimerʼs disease: present scenario. Neurol Sci 2013; 34: 831-839
• 15 Hardy JA, Higgins GA. Alzheimerʼs disease: the amyloid cascade hypothesis. Science 1992; 256: 184-185
• 16 De Strooper B, Vassar R, Golde T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol 2010; 6: 99-107
• 17 Masters CL, Selkoe DJ. Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb Perspect Med 2012; 2: 1-24
• 18 Krstic D, Knuesel I. Deciphering the mechanism underlying late-onset Alzheimer disease. Nat Rev Neurol 2013; 9: 25-34
• 19 Anand R, Gill KD, Mahdi AA. Therapeutics of Alzheimerʼs disease: past, present and future. Neuropharmacol 2014; 76: 27-50
• 20 Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimerʼs disease. Lancet 1976; 8000: 1403
• 21 Mufson EJ, Counts SE, Perez SE, Ginsberg SD. Cholinergic system during the progressing of Alzheimerʼs disease: Therapeutic implications. Expert Rev Neurother 2008; 8: 1703-1718
• 22 Munoz-Torrero D. Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimerʼs disease. Curr Med Chem 2008; 15: 2433-2455
• 23 Tayeb HO, Yang HD, Price BH, Tazari FI. Pharmacotherapies for Alzheimerʼs disease: Beyond cholinesterase inhibitors. Pharmacol Ther 2012; 134: 8-25
• 24 Sun X, Jin L, Ling P. Review of drugs for Alzheimerʼs disease. Drug Discov Ther 2012; 6: 285-290
• 25 Nordberg A, Ballard C, Bullock R, Darreh-Shori T, Somogyi M. A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimerʼs disease. Prim Care Companion CNS Disord 2013; 15
• 26 Ellman GL, Courtney KD, Anders Jr V, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961; 7: 88-95
• 27 Järvinen P, Vuorela P, Hatakka A, Fallarero A. Potency determinations of acetylcholinesterase inhibitors using Ellmanʼs reaction based assay in screening: Effect of assay variants. Anal Biochem 2011; 408: 166-168
• 28 Marston A, Kissling J, Hostettmann K. A rapid TLC bioautographic method for the detection of acetylcholinesterase and butyrylcholinesterase inhibitors in plants. Phytochem Anal 2002; 13: 51-54
• 29 Di Giovannia S, Borlozb A, Urbainb A, Marston A, Hostettmann K, Carrupta PA, Reista M. In vitro screening assays to identify natural or synthetic acetylcholinesterase inhibitors: Thin layer chromatography versus microplate methods. Eur J Pharm Sci 2008; 33: 109-119
• 30 Karlsson D, Fallarero A, Brunhofer G, Guzik P, Prinz M, Holzgrabe U, Erker T, Vuorela P. Identifying and characterization of diarylimidazoles as hybrid inhibitors of butyrylcholinesterase and amyloid beta fiblil formation. Eur J Pharm Sci 2012; 45: 169-183
• 31 Ingkaninan K, de Best CM, van der Heijden R, Hofte AJP, Karabatak B, Irth H, Tjaden UR, van der Greef J, Verpoorte R. High-performance liquid chromatography with on-line coupled UV, mass spectrometric and biochemical detection for identification of acetylcholinesterase inhibitors from natural products. J Chromatog A 2000; 872: 61-73
• 32 Mukherjee PK, Kumar V, Mal M, Houghton PJ. Acetylcholinesterase inhibitors from plants. Phytomedicine 2007; 14: 289-300
• 33 Orhan I, Sener B, Choudhary IM, Khalid A. Acetylcholinesterase and butyrylcholinesterase inhibitory activity of some Turkish medicinal plants. J Ethnopharmacol 2004; 91: 57-60
• 34 Andersen A, Gauguin B, Gudiksen L, Jäger AK. Screening of plants used in Danish folk medicine to treat memory dysfunction for acetylcholinesterase inhibitory activity. J Ethnopharmacol 2006; 104: 418-422
• 35 Ferreira A, Proença C, Serralheiro MLM, Araujo MEM. The in vitro screening for acetylcholinesterase inhibition and antioxidant activity of medicinal plants from Portugal. J Ethnopharmacol 2006; 108: 31-37
• 36 Mukherjee PK, Kumar V, Houghton PJ. Screening of Indian medicinal plants for acetylcholinesterase inhibitory activity. Phytother Res 2007; 21: 1142-1145
• 37 Loizzo MR, Tundis R, Conforti F, Menichini F, Bonesi M, Nadjafi F, Frega NG, Menchini F. Salvia leriifolia Benth (Laminaceae) extract demonstrates antioxidant properties and cholinesterase inhibitory activity. Nutr Res 2010; 30: 823-830
• 38 Khan M, Elhussein SAA, Khan MM, Khan N. Anti-acetylcholinesterase activity of Piper sarmentosum by a continuous immobilized-enzyme assay. APCBEE Procedia 2012; 2: 199-204
• 39 Cespedes CL, Muñoz E, Salazar JR, Yamaguchi L, Werner E, Alarcon J, Kubo I. Inhibition of cholinesterase activity by extracts, fractions and compounds from Calceolaria talcana and C. integrifolia (Calceolariaceae: Scrophulariaceae). Food Chem Toxicol 2013; 62: 919-926
• 40 Lai DH, Yang ZD, Xue WW, Sheng J, Shi Y, Yao XJ. Isolation, characterization and acetylcholinesterase inhibitory activity of alkaloids from roots of Stemona sessilifolia . Fitoterapia 2013; 89: 257-264
• 41 Dvira H, Silmanb I, Harela M, Rosenberryc TL, Sussmana JL. Acetylcholinesterase: from 3D structure to function. Chem Biol Interact 2010; 187: 10-22
• 42 Ryšlavá H, Doubnerová V, Kavan D, Vaněk O. Effect of posttranslational modifications on enzyme function and assembly. J Proteomics 2013; 92: 80-109
• 43 Massoulié J, Perrier N, Noureddine H, Liang D, Bon S. Old and new questions about cholinesterases. Chemical Biol Interact 2008; 75: 30-44
• 44 Ramachandran S, Rami BR, Udgaonkar JB. Measurements of cysteine reactivity during protein unfolding suggest the presence of competing pathways. J Mol Biol 2000; 297: 733-745
• 45 Sakurada K, Ikegaya H, Ohta H, Akutsu T, Takatori T. Hydrolysis of an acetylthiocholine by pralidoxime iodide (2-PAM). Toxicol Lett 2006; 166: 255-260
• 46 Veloso AJ, Nagy PM, Zhang B, Dhar D, Liang A, Ibrahim T, Mikhaylichenko S, Aubert I, Kerman K. Miniaturized electrochemical system for cholinesterase inhibitor detection. Anal Chim Acta 2013; 774: 73-78
• 47 Min W, Wang W, Chen J, Wang A, Hu Z. On-line immobilized acetylcholinesterase microreactor for screening of inhibitors from natural extracts by capillary electrophoresis. Anal Bioanal Chem 2012; 404: 2397-2405
• 48 Yang ZD, Song ZW, Ren J, Yang MJ, Li S. Improved thin-layer chromatography bioautographic assay for the detection of actylcholinesterase inhibitors in plants. Phytochem Anal 2011; 22: 509-515
• 49 Mullane K, Williams M. Alzheimerʼs therapeutics: Continued clinical failures question the validity of the amyloid hypothesis – but what lies beyond?. Biochem Pharmacol 2013; 85: 289-305
• 50 Hong L, Koelsch G, Lin X, Wu S, Terzyan S, Ghosh AK, Zhang XC, Tang J. Structure of the protease domain of memapsin 2 (β-secretase) complexed with inhibitor. Science 2000; 290: 150-153
• 51 Wang H, Li R, Shen Y. β-Secretase: its biology as a therapeutic target in diseases. TIPS 2013; 34: 215-225
• 52 Golde TE, Koo EH, Felsenstein KM, Osborne BA, Miele L. γ-Secretase inhibitors and modulators. Biochim Biophys Acta 2013; 1828: 2898-2907
• 53 Jeon SY, Kwon SH, Seong YH, Bae K, Hur JM, Lee YY, Suh DY, Song KS. β-secretase (BACE1)-inhibiting stilbenoids from Smilax Rhizoma. Phytomedicine 2007; 14: 403-408
• 54 Sasaki H, Miki K, Kinoshita K, Koyama K, Juliawaty LD, Achmad SA, Hakim EH, Kaneda M, Takahashi K. β-secretase (BACE-1) inhibitory effect of bioflavonoids. Bioorg Med Chem Lett 2010; 20: 4558-4560
• 55 Zhu Z, Li C, Wang X, Yang Z, Chen J, Hu L, Jiang H, Shen X. 2,2′,4′-trihydroxychalcone from Glycyrrhiza glabra as a new specific BACE1 inhibitor efficiently ameliorates memory impairment in mice. J Neurochem 2010; 114: 374-385
• 56 Tao J, Zhao J, Zhao Y, Cui Y, Fang W. BACE inhibitory flavanones from Balanophora involucrata Hook. f. Fitoterapia 2012; 83: 1386-1390
• 57 Hwang EM, Ryu YB, Kim HY, Kim DG, Hong SG, Lee JH, Curtis-Long MJ, Jeong SH, Park JY. BACE1 inhibitory effects of lavandulyl flavanones from Sophora flavescens . Bioorg Med Chem 2008; 16: 6669-6674
• 58 Vassar R, Kovacs DM, Yan R, Wong PC. The β-Secretase enzyme BACE in health and Alzheimerʼs disease: regulation, cell biology, function, and therapeutic potential. J Neurosci 2009; 29: 12787-12794
• 59 Small SA, Gandy S. Sorting through the cell biology of Alzheimerʼs disease: intracellular pathways to pathogenesis. Neuron 2006; 52: 15-31
• 60 Axelman K, Basun H, Winblad B, Lannfelt L. A large Swedish family with Alzheimerʼs disease with a codon 670/671 amyloid precursor protein mutation. A clinical and genealogical investigation. Arch Neurol 1994; 51: 1193-1197
• 61 Zhu F, Wu F, Ma Y, Liu G, Li Z, Sun Y, Pei Z. Decrease in the production of beta-amyloid by berberine inhibition of the expression of betasecretase in HEK293 cells. BMC Neuroscience 2011; 12
• 62 Kang IJ, Jeon YE, Yin XF, Nam JS, You SG, Hong MS, Jang BG, Kim MJ. Butanol extract of Ecklonia cava prevents production and aggregation of beta-amyloid, and reduces beta-amyloid mediated neuronal death. Food Chem Toxicol 2011; 49: 2252-2259
• 63 Cecchi C, Stefani M. The amyloid-cell membrane system. The interplay between the biophysical features of oligomers/fibrils and cell membrane defines amyloid toxicity. Biophys Chem 2013; 182: 30-43
• 64 Vepsäläinen S, Koivisto H, Pekkarinen E, Mäkinen P, Dobson G, McDougall GJ, Stewart D, Haapasalo A, Karjalainen RO, Tanila H, Hiltunen M. Anthocyanin-enriched bilberry and blackcurrant extracts modulate amyloid precursor protein processing and alleviate behavioral abnormalities in the APP/PS1 mouse model of Alzheimerʼs disease. J Nutr Biochem 2013; 24: 360-370
• 65 Hage S, Kleinlen-Campard P, Octave JN, Quetin-Leclerq J. In vitro screening on β-amyloid peptide production of plants used in traditional medicine for cognitive disorders. J Ethnopharmacol 2010; 131: 585-591
• 66 Lee TH, Part YI, Han YH. Effect of mycelial extract of Clavicorona pyxidata on the production of amyloid β-peptide and the inhibition of endogenous β-secretase activity. J Microbiol 2006; 44: 665-670
• 67 Findeis MA, Schroeder F, McKee TD, Yager D, Fraering PC, Creaser SP, Austin WF, Clardy J, Wang R, Selkoe D, Eckman CB. Discovery of a novel pharmacological and structural class of gamma secretase modulators derived from the extract of Actaea racemosa . ACS Chem Neurosci 2012; 21: 941-951
• 68 Hall A, Patel TR. γ-Secretase modulators: current status and future directions. Prog Med Chem 2014; 53: 101-145
• 69 Liu LF, Durairajan SSK, Lu JH, Koo I, Li M. In vitro screening on amyloid precursor protein modulation of plants used in ayurvedic and traditional Chinese medicine for memory improvement. J Ethnopharmacol 2012; 141: 754-760
• 70 Bignante EA, Heredia F, Morfini G, Lorenzo A. Amyloid β precursor protein as a molecular target for amyloid β-induced neuronal degeneration in Alzheimerʼs disease. Neurobiol Aging 2013; 34: 2525-2537
• 71 Haugabook SJ, Yager DM, Eckman EA, Golde TE, Younkin SG, Eckman CB. High throughput screens for the identification of compounds that alter the accumulation of the Alzheimerʼs amyloid peptide (Aβ). J Neurosci Meth 2001; 108: 171-179
• 72 Shimmyo Y, Kihara T, Akaike A, Niidome T, Sugimoto H. Flavonols and flavones as BACE-1 inhibitors: Structure–activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features. Biochim Biophys Acta 2008; 1780: 819-825
• 73 Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimerʼs disease: clinical trials and drug development. Lancet Neurol 2010; 9: 702-716
• 74 Dumont M, Flint Beal M. Neuroprotective strategies involving ROS in Alzheimer disease. Free Radical Biology Medicine 2011; 51: 1014-1026
• 75 Sutherland GT, Chami B, Youssef P, Witting PK. Oxidative stress in Alzheimers disease: Primary villain or physiological by-product?. Redox Report 2013; 18: 134-141
• 76 López-Alarcón C, Denicola A. Evaluating the antioxidant capacity of natural products: A review on chemical and cellular based assays. Anal Chim Acta 2013; 763: 1-10
• 77 Magalhães LM, Segundo MA, Reis S, Lima JLFC. Methodological aspects about in vitro evaluation of antioxidant properties. Anal Chim Acta 2008; 613: 1-19
• 78 Niki E. Assessment of antioxidant capacity in vitro and in vivo . Free Radical Biol Med 2010; 49: 503-515
• 79 Kamdem JP, Adeniran A, Boligon AA, Klimaczewski CV, Elekofehinti OO, Hassan W, Ibrahim M, Waczuk EP, Meinerz DF, Athayde ML. Antioxidant activity, genotoxicity and cytotoxicity evaluation of lemon balm (Melissa officinalis L.) ethanolic extract: Its potential role in neuroprotection. Ind Crops Prod 2013; 51: 26-34
• 80 Venkatachalam RN, Singh K, Marar T. Phytochemical screening and in vitro antioxidant activity of Psidium guaja . Free Rad Antiox 2012; 2: 31-36
• 81 Arruda M, Viana H, Rainha N, Neng NR, Rosa JS, Nogueira JMF, do Carmo Barreto M. Anti-acetylcholinesterase and antioxidant activity of essential oils from Hedychium gardnerianum Sheppard ex Ker-Gawl. Molecules 2012; 17: 3082-3092
• 82 Orhan IE, Suntar IP, Akkol EK. In vitro neuroprotective effects of the leaf and fruit extracts of Juglans regia L. (walnut) through enzymes linked to Alzheimerʼs disease and antioxidant activity. Int J Food Sci Nutr 2011; 62: 781-786
• 83 Wong DZH, Kadir HA, Ling SK. Bio-assay guided isolation of neuroprotective compounds from Loranthus parasiticus against H₂O₂-induced oxidative damage in NG108–15 cells. J Ethnopharmacol 2012; 139: 256-264
• 84 Zhao Y, Dou J, Wu T, Aisa HA. Investigating the antioxidant and acetylcholinesterase inhibition activities of Gossypium herbaceam . Molecules 2013; 18: 951-962
• 85 Xiao Z, Huang C, Wu J, Sun L, Hao W, Leung LK, Huang J. The neuroprotective effects of ipriflavone against H₂O₂ and amyloid beta induced toxicity in human neuroblastoma SH-SY5Y cells. Eur J Pharmacol 2013; 721: 286-293
• 86 Custódio L, Patarra J, Alberício F, Neng NR, Nogueira JMF, Romano A. Extracts from Quercus sp. acorns exhibit in vitro neuroprotective features through inhibition of cholinesterase and protection of the human dopaminergic cell line SH-SY5Y from hydrogen peroxide-induced cytotoxicity. Ind Corps Prod 2013; 45: 114-120
• 87 Ha SK, Moon E, Ju MS, Kim DH, Ryu JH, Oh MS, Kim SY. 6-shogaol, a ginger product, modulates neuroinflammation: A new approach to neuroprotection. Neuropharmacol 2012; 63: 211-223
• 88 Figuera-Losasa M, Rojas C, Slusher BS. Inhibition of microglia activation as a phenotypic assay in early drug discovery. JBS 2014; 19: 17-31
• 89 Masters CL, Simms G, Weinman NA, Multhaupt G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci 1985; 83: 4245-4249
• 90 Hardy J. Framing β-amyloid. Nat Gen 1992; 1: 233-234
• 91 Imtiaz B, Tolppanen AM, Kivipelto M, Soininen H. Future directions in Alzheimerʼs disease from risk factors to prevention. Biochem Pharmacol 2014; 88: 661-670
• 92 Macarrón R, Hertzberg RP. Design and implementation of high throughput screening assays. Mol Biotechnol 2011; 47: 270-285
• 93 Lee JA, Uhlik MT, Moxham CM, Tomandl D, Sall DL. Modern phenotypic drug discovery is a viable, neoclassic strategy. J Med Chem 2012; 55: 4527-4538
• 94 Butera J. Phenotypic screening as a strategic component of drug discovery programs targeting novel antiparasitic and antimycobacterial agents. J Med Chem 2013; 56: 7715-7718
• 95 Swinney DC. The contribution of mechanistic understanding to phenotypic screening for first-in-class medicines. J Biomol Screen 2013; 18: 1186-1192
• 96 Lee LA, Berg EL. Neoclassic drug discovery: The case for lead generation using phenotypic and functional approaches. J Biomol Screen 2013; 18: 1145-1155
• 97 Winquist RJ, Mullane K, Williams M. The fall and rise of pharmacology – (Re)defining the discipline?. Biochem Pharmacol 2014; 87: 4-24